[
  {
    "ts": null,
    "headline": "BMS to acquire longtime cell therapy partner 2seventy bio for $286m",
    "summary": "The deal comes after a challenging few years for 2seventy bio, which had divested research programmes in recent years.",
    "url": "https://finnhub.io/api/news?id=bc1baa43c5a31742cb126d9365cfd1594fcc3ad6e26b40b1261c49b4b152ba08",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741730248,
      "headline": "BMS to acquire longtime cell therapy partner 2seventy bio for $286m",
      "id": 133185682,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The deal comes after a challenging few years for 2seventy bio, which had divested research programmes in recent years.",
      "url": "https://finnhub.io/api/news?id=bc1baa43c5a31742cb126d9365cfd1594fcc3ad6e26b40b1261c49b4b152ba08"
    }
  },
  {
    "ts": null,
    "headline": "TSVT Up on Acquisition Agreement With BMY for $286 Million",
    "summary": "2seventy bio agrees to be acquired by partner BMY for $286 million. Shares gain.",
    "url": "https://finnhub.io/api/news?id=a41b02a8bbe117f42a20611b12942396d98c0a9b840fb686a9ecab97968ed587",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741719600,
      "headline": "TSVT Up on Acquisition Agreement With BMY for $286 Million",
      "id": 133185683,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "2seventy bio agrees to be acquired by partner BMY for $286 million. Shares gain.",
      "url": "https://finnhub.io/api/news?id=a41b02a8bbe117f42a20611b12942396d98c0a9b840fb686a9ecab97968ed587"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors",
    "summary": "Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=3c7c2a12e2af2e9f2b1ecd6ab4f32930347e1f4a2e89d8f49f2f38b2225d464e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741711020,
      "headline": "Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors",
      "id": 133153117,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=3c7c2a12e2af2e9f2b1ecd6ab4f32930347e1f4a2e89d8f49f2f38b2225d464e"
    }
  },
  {
    "ts": null,
    "headline": "Legend Biotech's Carvykti Is Taking Off, And It's Still Early (Rating Upgrade)",
    "summary": "Carvykti's success boosts Legend Biotech Corporation's Q4 2024 sales to $334M, solidifying market position. Click for my updated look at LEGN earnings.",
    "url": "https://finnhub.io/api/news?id=9f1910c5e487ba2c0ff679899a263343373f86252cee9e7c7170cdfe7c22f59d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741710774,
      "headline": "Legend Biotech's Carvykti Is Taking Off, And It's Still Early (Rating Upgrade)",
      "id": 133139425,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2189063052/image_2189063052.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Carvykti's success boosts Legend Biotech Corporation's Q4 2024 sales to $334M, solidifying market position. Click for my updated look at LEGN earnings.",
      "url": "https://finnhub.io/api/news?id=9f1910c5e487ba2c0ff679899a263343373f86252cee9e7c7170cdfe7c22f59d"
    }
  },
  {
    "ts": null,
    "headline": "Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It",
    "summary": "Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis. Click fo rmy PTGX update.",
    "url": "https://finnhub.io/api/news?id=9e0337c08ddb883be885c55f1206f206b8fb08bfd2f83fd9ca8c00378b311f90",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741708809,
      "headline": "Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It",
      "id": 133139254,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194222145/image_2194222145.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis. Click fo rmy PTGX update.",
      "url": "https://finnhub.io/api/news?id=9e0337c08ddb883be885c55f1206f206b8fb08bfd2f83fd9ca8c00378b311f90"
    }
  },
  {
    "ts": null,
    "headline": "ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc.",
    "summary": "NEW YORK, March 11, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by 2seventy bio, Inc. and its board of directors concerning the proposed acquisition of...",
    "url": "https://finnhub.io/api/news?id=8a6a1c9c7261a09973ca016c0b05f5f5d2ccdfbed3a2da0dfba43ee39dee8e38",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741707125,
      "headline": "ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc.",
      "id": 133138831,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "NEW YORK, March 11, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by 2seventy bio, Inc. and its board of directors concerning the proposed acquisition of...",
      "url": "https://finnhub.io/api/news?id=8a6a1c9c7261a09973ca016c0b05f5f5d2ccdfbed3a2da0dfba43ee39dee8e38"
    }
  },
  {
    "ts": null,
    "headline": "BMEZ: Recession Fears Making You Sick? Buy This High-Yield Healthcare Fund",
    "summary": "BlackRock Health Sciences Term Trust is a top pick for high-yield dividends in healthcare. Click here to find out why BMEZ stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=0a90bbc72c21544b52437a24252fdcd27158f61d0b5128e17ea6b2ed0058f641",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741698125,
      "headline": "BMEZ: Recession Fears Making You Sick? Buy This High-Yield Healthcare Fund",
      "id": 133136036,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2148098716/image_2148098716.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "BlackRock Health Sciences Term Trust is a top pick for high-yield dividends in healthcare. Click here to find out why BMEZ stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=0a90bbc72c21544b52437a24252fdcd27158f61d0b5128e17ea6b2ed0058f641"
    }
  },
  {
    "ts": null,
    "headline": "2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M",
    "summary": "The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly all of its market value.",
    "url": "https://finnhub.io/api/news?id=3d04ac812dfee3ec43a531028d4869249769dcdc75ccea77db3abd3c022e143c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741691100,
      "headline": "2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M",
      "id": 133185684,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly all of its market value.",
      "url": "https://finnhub.io/api/news?id=3d04ac812dfee3ec43a531028d4869249769dcdc75ccea77db3abd3c022e143c"
    }
  },
  {
    "ts": null,
    "headline": "2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers",
    "summary": "2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers",
    "url": "https://finnhub.io/api/news?id=9809591f104fd390b1bd3da0b61e0d45fba2511b21931dce768b1a97847217ec",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741672680,
      "headline": "2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers",
      "id": 133153119,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers",
      "url": "https://finnhub.io/api/news?id=9809591f104fd390b1bd3da0b61e0d45fba2511b21931dce768b1a97847217ec"
    }
  }
]